Stockhead’s Sarah Hughan sits down with Lumos Diagnostics’ (ASX:LDX) non-executive chair Sam Lanyon to get the short end of the long story on the company’s latest news.

The medtech’s FebriDx frontline screening test uses a fingerstick blood sample to aid in the differentiation between bacterial and viral infection.

It’s also attracting a lot of interest from industry stakeholders as well as retail investors with a recent $10M equity raising.

Tune in to hear Lumos Diagnostics’ Sam Lanyon on antimicrobial resistance, the services side of the business, and more.

 

This video was developed in collaboration with Lumos Diagnostics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.